icon- folder.gif   Conference Reports for NATAP  
 
  Conference on Retroviruses
and Opportunistic Infections
Denver, Colorado
March 3-6 2024
 		Back grey_arrow_rt.gif
 
 
 
Phase 1 Study of Cabotegravir Long-Acting
Injectable Formulations Supports ≥4-Monthly Dose Interval
 
 
  CROI 024 March 3-6 Denver

0306241

0306242

0306243

0306244

0306245